Symptom Duration Affects Teen Drug Trials
Posted on: Thursday, 14 September 2006, 21:00 CDT
The short duration of depressive symptoms in teens may affect evaluation of drug treatment responses, according to a U.S. study.
There has been controversy in recent years regarding the correlation between teenage suicide and the use of anti-depressant drugs and at a Federal Drug Administration meeting reviewing this topic, the majority of clinical trials examined did not show that the drugs were effective in treating depression in children and adolescents.
The study, published in the Journal of Clinical Pharmacology, suggests that the short duration of depressive symptoms in this age group makes it difficult to distinguish drug efficacy from placebo.
The researchers advise using multiple assessments to establish a continuous baseline before randomizing patients to treatment, which would remove those who spontaneously recover in a very short period of time.
In addition to having an impact on the accuracy of future clinical trials, this approach may help decrease the number of children who are exposed to unnecessary long-term drug therapy and possible side effects, since those who spontaneously recover quickly would not be started on drug therapy.
Source: United Press International
Related Articles
- TB Alliance Advances Two Drugs in Clinical Trials on Path to Faster, Better Tuberculosis Treatments
- FDA Releases Memory Drug From Clinical Hold
- Athersys Cleared to Move Obesity Drug into Clinic
- Metabasis' Type 2 Diabetes Drug Enters Clinic
- Profiling Several Drugs in Clinical Development That Are Expected to Change the Standard of Care for Transplant Patients By 2010
- 340B Prime Vendor Program Adds NitroMed, Inc. To Growing List of Companies Providing Low-Cost Drugs to Clinics, Hospitals and Programs for Low-Income Americans
- Novartis Hypertension Drug Achieves Clinical Success in Phase III
- NovImmune Seeks to Move Autoimmune Drug into Clinic
- Study:School Nurses Need More Help *** Many Districts Short, Clinics Help Fill Gap
- Promising New Tuberculosis Drug Enters Clinical Trial
 |
 |
User Comments (0)
RSS Feeds